Informational service

GLP-1 consultation

A medical evaluation to determine eligibility and options.

Service information · no outcome promiseAsk about this service

01 / Clinical Exploration

Four points of the clinical protocol

Explore the four key procedural areas and their corresponding therapeutic criteria.

Conceptual visual of a medical consultation

Step 01/of 4·History

Informational service

Clinical history and metabolic context

Medical consultation examines weight trajectory, nutritional habits, family history, and medications.

Protocol criteria

Detailed review of personal, family, and endocrine medical history
Evaluation of prior lifestyle interventions and metabolic patterns
Baseline metabolic panel, lipid profile, and thyroid/pancreatic status

Specific clinical limit

Medical consultation is an evaluation; it does not guarantee issuance of a prescription.

Complete reading view of the clinical protocol (no-JavaScript mode):

01 — History

Clinical history and metabolic context

Medical consultation examines weight trajectory, nutritional habits, family history, and medications.

Protocol criteria:

Detailed review of personal, family, and endocrine medical history
Evaluation of prior lifestyle interventions and metabolic patterns
Baseline metabolic panel, lipid profile, and thyroid/pancreatic status

Weight management with GLP-1 receptor agonists is a formal medical treatment. The initial consultation establishes a physician-patient relationship centered on metabolic health rather than cosmetic pressures.

Medical consultation is an evaluation; it does not guarantee issuance of a prescription.

02 — Eligibility

Clinical eligibility criteria

Absolute and relative contraindications are evaluated strictly under FDA and clinical guidelines.

Protocol criteria:

Body Mass Index (BMI) assessment and documentation of weight-related comorbidities
Exclusion of personal or family history of medullary thyroid carcinoma or MEN-2
Absence of active pancreatitis, severe gastrointestinal disease, or gallstones

GLP-1 receptor agonists are indicated for chronic weight management in adults with BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes). Meeting these criteria is mandatory.

Not prescribed for cosmetic weight reduction in individuals within normal weight ranges.

03 — Decision

Shared clinical decision-making

Physician and patient evaluate therapeutic benefits, common side effects, and alternatives together.

Protocol criteria:

Transparent discussion of common gastrointestinal symptoms and mitigation
Informed consent regarding the chronic nature of metabolic management
Structured gradual dose titration schedule to optimize tolerance

Treatment decisions address not only initiating therapy but also managing transient nausea, delayed gastric emptying, and understanding that long-term adherence is needed to preserve metabolic benefits.

GLP-1 medications are one component; they require foundational nutritional support and resistance exercise.

04 — Follow-up

Ongoing physician supervision

Regular clinical reviews monitor metabolic progress, lean mass retention, and treatment tolerance.

Protocol criteria:

Periodic follow-up consultations and monitoring blood panels
Preservation of lean muscle mass supported by adequate protein intake and resistance training
Individualized maintenance dosing or structured discontinuation planning

Ongoing medical oversight ensures that weight reduction preserves functional muscle mass and protects nutritional health. Follow-up visits adjust titration according to personal response and health markers.

Abrupt unguided discontinuation can lead to weight regain and reversal of metabolic markers.

Information for your decision

What it is

This consultation reviews your history, medications, goals, and risk factors to determine whether an authorized prescription option is appropriate. The service is published without promises of weight loss or metabolic outcomes.

What we review

Medical history and current medications
Eligibility criteria and contraindications
Options, risks, and alternatives
Follow-up plan if treatment is prescribed

Evidence boundary

Compounded versions are not offered as an automatic substitute for approved medications, and no outcome promises are published.

Educational information only; not a substitute for medical advice, diagnosis, or treatment. Eligibility, protocol, and outcomes vary by person and indication.

The clinical journey in three steps

What is evaluated

Medical history, current medications, risk factors and goals. The physician determines whether an authorized prescription option is appropriate based on eligibility criteria.

How the consultation proceeds

Review of options, risks and alternatives. Informed consent. The evaluation does not guarantee a prescription; any decision requires clinical judgment.